Central European journal of urologyOct 22, 2026

What Urologists Should Know About Weight Loss and Kidney Stones with Glucagon-Like Peptide-1 Receptor Agonists

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 23, 2026

Abstract

Obesity and type 2 diabetes mellitus are associated with increased risk of urolithiasis due to adverse changes in urinary chemistry.

Lower urine pH and higher lithogenic supersaturation are observed in individuals with obesity and type 2 diabetes.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for managing glycemic control and weight loss.
The implications of GLP-1RAs for patients prone to kidney stones require further clarification.

Simplified

Obesity and type 2 diabetes mellitus are closely linked to urolithiasis risk through adverse urinary chemistry, including lower urine pH and higher lithogenic supersaturation. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for glycemic control and weight loss, creating a need to clarify their implications for stone-forming patients.

What Urologists Should Know About Weight Loss and Kidney Stones with Glucagon-Like Peptide-1 Receptor Agonists

Abstract

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief